Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial

Lancet

Volumn 361, Issue 9369, 2003, Pages 1597-1602

  Nisbet Brown, Eric ^a,d   Olivieri, Nancy F ^c,e   Giardina, Patricia J ^b,f   Grady, Robert W ^b,f   Neufeld, Ellis J ^a,d   Séchaud, Romain ^g   Krebs Brown, Axel J ^g   Anderson, Judith R ^g   Alberti, Daniele ^g   Sizer, Kurt C ^g   Nathan, David G ^a,d,h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERASIROX; IRON; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIETARY INTAKE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ERYTHROCYTE; EXCRETION; FECES ANALYSIS; FEMALE; FEVER; FOOD INTAKE; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; HYPOTENSION; INFECTION; LABORATORY; MALE; MEASUREMENT; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECORDING; RETINA BLOOD VESSEL OCCLUSION; SIDE EFFECT; STEADY STATE; THALASSEMIA; URINE VOLUME;

EID: 10744230223     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13309-0     Document Type: Article

References (27)

1. Pippard M.J., Weatherall D.J. Oral iron chelation therapy for thalassaemia: an uncertain scene. Br J Haematol. 111:2000;2-5.
2. Porter J.B. Practical management of iron overload. Br J Haematol. 115:2001;239-252.
3. Wolfe L., Olivieri N., Sallan D., et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 312:1985;1600-1603.
4. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 331:1994;574-578.
5. Badman D.G., Bergeron R.J., Brittenham G.M. Iron chelators: new development strategies. 2000;The Saratoga Group, Ponte Verde Beach.
6. Hider R.C., Singh S., Porter J.B., Huehns E.R. The development of hydroxypyridin-4-ones as orally active iron chelators. Ann N Y Acad Sci. 612:1990;327-338.
7. Olivieri N.F., Brittenham G.M., Matsui D., et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 332:1995;918-922.
8. Hoffbrand A.V., Al-Refaie F., Davis B., et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 91:1998;295-300.
9. Cohen A.R., Galanello R., Piga A., Dipalma A., Vullo C., Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 108:2000;305-312.
10. Olivieri N.F., Brittenham G.M., McLaren C.E., et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 339:1998;417-423.
11. Nick H.P., Acklin P., Faller B., et al. A new, potent, orally active iron chelator. Badman D.G., Bergeron R.J., Brittenham G.M. Iron chelators: new development strategies. 2000;311-333 The Saratoga Group, Ponte Verde Beach.
12. Singh S., Epemolu R.O., Dobbin P.S., et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl- substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos. 20:1992;256-261.
13. 1) in patients with iron overload. Br J Haematol. 89:1995;403-408.
14. Töndury P., Zimmermann A., Nielsen P., Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol. 101:1998;413-415.
15. Del Vecchio G.C., Crollo E., Schettini F., Fischer R., De Mattia D. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematol. 104:2000;99-102.
16. Mazza P., Amurri B., Lazzari G., et al. Oral iron chelating therapy, a single centre interim report on deferiprone (L1) in thalassemia. Haematologica. 83:1998;496-501.
17. Naylor C.D. The deferiprone controversy: time to move on. CMAJ. 166:2002;452-453.
18. Wanless I.R., Sweeney G., Dhillon A.P., et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 100:2002;1566-1569.
19. Ryabukhin Yu I., Shibaeva N.V., Kuzharov A.S., Korobkova V.G., Khokhlov A.V., Garnovskii A.D. Preparation and study of transition metal complexes with di(o-hydroxyphenyl)-1,2,4-oxadiazole and 1,2,4-triazole. Sov J Coord Chem (Engl Transl). 13:1987;493-499.
20. Heinz U., Hegetschweiler K., Acklin P., Faller B., Lattmann R., Schnebli H.P. 4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid: a novel efficient and selective iron(III) complexing agent. Angew Chem Int Ed. 38:1999;2568-2570.
21. Rouan M.C., Marfil F., Mangoni P., Séchaud R., Humbert H., Maurer G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr. 755:2001;203-213.
22. Mallal S., Nolan D., Witt C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359:2002;727-732.
23. Arnaiz-Villena A., Dimitroski K., Pacho A., et al. HLA genes in Macedonians and the sub-Saharan origin of the Greeks. Tissue Antigens. 57:2001;118-127.
24. Varnavidou-Nicolaidou A., Karpasitis S., Papaleontiou I., Kyrakides G.K. HLA-A, -B, -DR Antigens in the Greek Cypriot population. Transplant Proc. 29:1997;2920-2921.
25. Papassavas E.C., Spyropoulou-Vlachou M., Papassavas A.C., Schipper R.F., Doxiadis I.N., Stavropoulos-Giokas C. MHC class I and class II phenotype, gene, and haplotype frequencies in Greeks using molecular typing data. Hum Immunol. 61:2000;615-623.
26. Breur W., Hershko C., Cabantchik Z.I. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci. 23:2000;185-192.
27. Piga A., Galanello R., Cappellini M.D., et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood. 100:2002;5a.